Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Research analysts at Oppenheimer Holdings issued their Q1 2018 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a research note issued on Monday. Oppenheimer Holdings analyst D. Archila expects that the biopharmaceutical company will post earnings of ($0.15) per share for the quarter. Oppenheimer Holdings has a “Buy” rating and a $21.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ Q2 2018 earnings at ($0.07) EPS, FY2018 earnings at ($0.10) EPS, FY2019 earnings at $0.29 EPS and FY2020 earnings at $0.72 EPS.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The company had revenue of $42.06 million during the quarter, compared to analysts’ expectations of $40.31 million. During the same quarter in the prior year, the company earned $0.01 EPS. The firm’s revenue was up 16.7% on a year-over-year basis.
WARNING: “Oppenheimer Holdings Comments on Vanda Pharmaceuticals Inc.’s Q1 2018 Earnings (VNDA)” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/10/12/oppenheimer-holdings-comments-on-vanda-pharmaceuticals-inc-s-q1-2018-earnings-vnda.html.
Institutional investors and hedge funds have recently modified their holdings of the company. Legal & General Group Plc boosted its stake in shares of Vanda Pharmaceuticals by 37.4% during the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 3,022 shares during the period. Kopp Investment Advisors LLC purchased a new stake in shares of Vanda Pharmaceuticals during the second quarter valued at $196,000. Virginia Retirement Systems ET AL purchased a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at $193,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at $196,000. Finally, Voya Investment Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 29.7% during the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 4,605 shares during the period. 86.49% of the stock is owned by hedge funds and other institutional investors.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
What are top analysts saying about Vanda Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vanda Pharmaceuticals Inc. and related companies.